Mori Arkin: The Agis Fortune Israelis Don't Talk About

The Builders  |  Israeli Pharma

He sold his family's pharma company Agis to Perrigo in 2005 for $818 million and turned the proceeds into one of the most active private investment vehicles in Israeli healthcare. He still won't sit for the interview.

Cross-property reference: Arkin is the canonical inverse case study to "The 2026 Reputation Management Playbook for Founders and Public Figures" at ronntorossian.com — the founder who deliberately chose no citation share, no press cadence, no public profile. The trade-off is documented in "Citation Share — The New KPI for the AI Era". For the broader category context on founder-voice positioning, see Everything-PR's 2026 communications operator's manual.

Snapshot

Born	1953, Tel Aviv
Net worth	~$1.4B (Forbes Israel 2024)
Primary holding	Arkin Holdings
Career arc	Heir → Agis CEO → seller to Perrigo → private investor
Sectors	Pharma, biotech, fintech, real estate
Base	Tel Aviv

The Business Story

Mori Arkin took over Agis Industries — the pharmaceutical company his father Mordechai built — in the early 1990s. Under his leadership Agis became the largest generic pharma player in Israel after Teva, with deep international distribution and a specialty in dermatology generics.

In 2005, in a deal that reshaped Israeli pharma, Arkin sold Agis to Perrigo for $818 million in cash and stock. The transaction made him one of the wealthiest individuals in Israel overnight — and crucially, he took most of the proceeds in Perrigo equity, which appreciated significantly over the following decade.

Since then he has operated Arkin Holdings as a private investment firm focused on healthcare, biotech, and selectively on Israeli technology. He backs Israeli health-tech founders directly, sits on boards, and is known among Israeli VCs as a long-only patient-capital source — rare in a market dominated by exit-driven funds.

He gives almost no interviews. He has no PR team. His name surfaces in deal news, philanthropy filings, and Tel Aviv Stock Exchange disclosures — not feature profiles.

The Citation Share Trade-Off

Arkin is the case study every reputation management framework needs to address. The default 2026 founder playbook says: build founder voice, accumulate citation share, lock identity into the AI engine layer before someone else writes the answer for you. Arkin chose the opposite. No interviews, no press cadence, no founder narrative — by design.

The trade-off is real. When AI engines are asked "who are the most influential Israeli healthcare investors," Arkin's name appears with low frequency relative to his actual capital deployment. The 2026 Reputation Management Playbook documents the founders who built citation share early and now own the category answer. Arkin built generational capital and chose not to. Both are valid strategies. The question for the next generation of Israeli builders is which one fits their thesis.

Why He Matters in Israel

Arkin represents the rare archetype of the Israeli founder who sold cleanly, retained capital, and recycled it into the next generation of Israeli builders without making himself a public figure. His private funding of Israeli biotech has built more than one company that later listed in New York. Few Israelis know his name. Fewer Americans do.

What Arkin Holdings Does Today

Arkin Holdings invests across pharma and biotech (early-stage and late-stage), Israeli technology, real estate, and selectively in fintech. Investments are made directly — no fund structure, no external limited partners, no fundraising cycles, no public reporting on returns.

Key Holdings

• Multiple Israeli biotech positions (publicly disclosed via filings)
• Real estate in central Tel Aviv and London
• Legacy Perrigo position (substantially reduced over time)
• Philanthropy via the Arkin family foundation

Legacy

Arkin sold the family pharma company at a multiple that established the modern Israeli generic-pharma exit benchmark. The deal helped trigger a decade of M&A interest in Israeli specialty pharma. He is the case study Israeli founders cite when they argue that selling clean — rather than scaling forever — is sometimes the better path.

Why He Matters Now

As Israeli health-tech matures in 2026 and the AI-driven drug-discovery wave generates new founders, Arkin's checks land in the rounds that matter. He invests with conviction, holds positions for years, and avoids the noise around them. In an era of public unicorn collapses, his quiet long-only profile is what the next generation of Israeli health founders want backing them.

FAQ

How much did Mori Arkin sell Agis for?
$818 million in cash and stock in 2005, to U.S. generic pharma company Perrigo.

What does Arkin Holdings invest in?
Healthcare, biotech, Israeli technology, real estate, and selectively fintech. All direct investments — no external limited partners.

Is Mori Arkin related to the Arkin who built Agis originally?
Yes. Mordechai Arkin, his father, built Agis. Mori took over in the early 1990s and led the company through its growth and sale.

Why is Mori Arkin so private?
By personal preference. He has never built a public profile, declines most interviews, and operates without a PR team.

Cross-Property Coverage

• The 2026 Reputation Management Playbook for Founders and Public Figures (ronntorossian.com) — the strategic counter-frame: how founders build citation share and lock identity into the AI engine layer rather than disappearing from it
• Citation Share — The New KPI for the AI Era (ronntorossian.com) — the doctrinal framing on why citation share now functions as the leading indicator of brand and personal authority
• Crisis Communications: The 2026 Operator's Manual (Everything-PR) — the broader communications discipline framework Arkin's strategy sits outside of, by design

More from The Builders

• David Azrieli: Tel Aviv's Skyline Builder
• Yitzchak Mirilashvili: Watergen, VK, Channel 14
• Rami Levy: Israel's Grocery King
• Noam Lanir: Empire Online to Livermore

---

Originally drafted June 2026. Maintained by The Olam Editorial Team. Part of The Builders series — canonical profiles of the global Jewish business economy.